Back to results

TerminatedPhase 2

Study to Evaluate Safety and Daytime Sedation in Subjects With Parkinson's Disease With Neuropsychiatric Symptoms Treated With Pimavanserin or Low-Dose Quetiapine

NCT04164758

What is this trial?

Generating plain-language summary...

Am I eligible?

Generating eligibility summary...

What's involved?

Summarizing study design...

Where and how to apply

Primary location

Movement Disorders Center of Arizona

Scottsdale, Arizona, United States

+15 additional locations

View on ClinicalTrials.gov

Save this trial

Quick facts

Start date: 2019-10-23
Enrollment: 11 participants
Sponsor: ACADIA Pharmaceuticals Inc.
Purpose: treatment

Locations (16)

Movement Disorders Center of ArizonaScottsdale, Arizona, United States
Tucson Neuroscience ResearchTucson, Arizona, United States
Sutter Institute for Medical ResearchSacramento, California, United States
Galiz ResearchHialeah, Florida, United States
Charter Research, LLCLady Lake, Florida, United States
Premier Clinical Research Institute, Inc.Miami, Florida, United States
Infinity Clinical Research, LLCSunrise, Florida, United States
Charter Research, LLCWinter Park, Florida, United States
Meridian Clinical ResearchSavannah, Georgia, United States
Hawaii Pacific Neuroscience, LLC.Honolulu, Hawaii, United States
University of lowa Hospital and ClinicsIowa City, Iowa, United States
SRI InternationalPlymouth, Michigan, United States
Bio Behavioral HealthToms River, New Jersey, United States
M3 Wake Research, Inc.Raleigh, North Carolina, United States
Dayton Center for Neurological DisordersCenterville, Ohio, United States
Prisma Health-UpstateGreenville, South Carolina, United States

Study to Evaluate Safety and Daytime Sedation in Subjects With Parkinson's Disease With Neuropsychiatric Symptoms Treated With Pimavanserin or Low-Dose Quetiapine — TrialFind